A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

NCT04055168 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped It was decided to not run the Japanese cohorts in the study.

Conditions

Dyslipidemia

Interventions

DRUG: AZD6615
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]